ENT, Eye, and Respiratory
Developing therapeutic agents for applications in Otolaryngology, or Ear, Nose, and Throat, Ophthalmology (eye and eye disease) and Pulmonary/Respiratory (lung and/or breathing-related diseases) requires unique expertise. Studies within ENT typically include: allergy, ear infections, pneumonia, rhinitis, sinus infections, strep throat, and others.
While there is a steady pipeline of research and development within ENT, there is a significant unmet clinical need for more effective treatments to halt or reverse ocular diseases. Studies in this area include: cataracts, eye infections, glaucoma, macular degeneration, near-sighted corrective surgery, and others.
Millions of people worldwide suffer from ocular diseases that deteriorate their quality of life, and that number is expected to exponentially increase as the aging baby boomer generation is expected to double the number of elderly in the United States. Nearly 20% of the U.S. population, more than 72 million people, will be 65 years of age or older by the year 2030. By age 65, 1-in-3 Americans have some form of vision impairing eye disease. Conditions such as glaucoma, cataracts, macular degeneration and diabetic retinopathy are the most common age-related eye diseases.
There is also much work to be done in the area of Pulmonary and Respiratory diseases. Studies in these areas include: Acute Respiratory Distress Syndrome (ARDS), allergy, asthma, bronchitis, cystic fibrosis, emphysema, lung disease, pneumonia, sinus infections, smoking cessation, and others.
By partnering with Clinipace Worldwide, we can help manage your entire ENT, ophthalmology or respiratory drug development program or conduct an individual trial. Our experts bring extensive therapeutic experience in building a well-defined strategy and clinical plan to maximize the probable success of your drug candidate. Our clinical teams can help operationalize your study protocol, and provide unprecedented visibility into your studies through our unified technology platform, TEMPO™ eClinical.